Related Experiment Video
Updated: Jan 8, 2026

Differentiation of Human Pluripotent Stem Cells into Insulin-Producing Islet Clusters
Published on: June 23, 2023
LDHA induces beta cell dedifferentiation in diabetes through metabolic and epigenetic reprogramming
Xirui Li1,2, Haoqiang Gong2, Can Xiong2
1Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Aims/Hypothesis:
Pancreatic beta cell dedifferentiation underlies the reversible reduction in beta cell mass and function in diabetes. Exploratory research into interventional targets and adjuvant therapies to prevent or reverse beta cell dedifferentiation and transdifferentiation may provide evidence to support the effective treatment of diabetes, although the underlying molecular mechanism remains elusive.
Methods:
Lactate dehydrogenase A (LDHA) expression and activity were analysed in islets obtained from human donors with type 2 diabetes, hyperglycaemic db/db mice and a high-fat diet (HFD)-induced mouse model of diabetes. The impact of LDHA inhibition on beta cell function and identity was also investigated in HFD-fed mice and db/db mice. Chromatin immunoprecipitation (ChIP)-seq and RNA-seq were used to investigate the specific molecular mechanism underlying the effect of LDHA on histone H3 lysine 9 lactylation (H3K9la) increases and beta cell function under glucotoxic conditions.
Results:
We demonstrate that inhibition of LDHA effectively preserves beta cell identity, which not only delays disease progression in individuals with impaired fasting glucose, but also improves insulin output and glucose homeostasis in diabetic models. Mechanistically, activation of LDHA led to a marked increase in H3K9la in the promoter region of the beta cell dedifferentiation marker genes Sox9, Hes1 and Aldh1a3, and facilitated their transcription, thereby triggering beta cell dedifferentiation as well as impaired glucose homeostasis and beta cell function in mice.
Conclusions/Interpretation:
We unravelled the role of LDHA-mediated metabolic and epigenetic reprogramming in beta cell dedifferentiation during diabetes development. This study suggests that LDHA inhibition could be a novel therapeutic strategy for diabetes treatment.
Insights
Lactate dehydrogenase A (LDHA) inhibition preserves pancreatic beta cell identity and function, offering a potential new treatment for diabetes. This study reveals LDHA
Area of Science:
- Metabolic and Epigenetic Regulation in Diabetes
- Pancreatic Beta Cell Biology
- Molecular Mechanisms of Diabetes
Background:
- Pancreatic beta cell dedifferentiation is a key factor in diabetes, reducing beta cell mass and function.
- Understanding the molecular mechanisms of beta cell dedifferentiation is crucial for developing effective diabetes treatments.
- Interventional targets are needed to prevent or reverse beta cell dedifferentiation.
Purpose of the Study:
- To investigate the role of Lactate dehydrogenase A (LDHA) in pancreatic beta cell dedifferentiation.
- To explore LDHA inhibition as a potential therapeutic strategy for diabetes.
- To elucidate the molecular mechanisms linking LDHA, epigenetic modifications, and beta cell dysfunction.
Main Methods:
- Analysis of LDHA expression and activity in human diabetic islets and mouse models (db/db and HFD-induced).
- Assessment of LDHA inhibition effects on beta cell function and identity in diabetic mice.
- Chromatin immunoprecipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq) to study LDHA's impact on histone lactylation and gene expression.
Main Results:
- LDHA inhibition preserved beta cell identity, delayed disease progression in impaired fasting glucose, and improved glucose homeostasis in diabetic models.
- LDHA activation increased histone H3 lysine 9 lactylation (H3K9la) at key beta cell dedifferentiation marker genes (Sox9, Hes1, Aldh1a3).
- Increased H3K9la facilitated transcription of dedifferentiation markers, leading to impaired beta cell function and glucose homeostasis.
Conclusions:
- LDHA plays a critical role in metabolic and epigenetic reprogramming driving beta cell dedifferentiation in diabetes.
- LDHA-mediated histone lactylation is a key mechanism linking metabolic changes to beta cell dysfunction.
- Inhibition of LDHA represents a promising novel therapeutic strategy for managing and treating diabetes.
Related Concept Videos
Forced Transdifferentiation
Artificial...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Tissue Renewal without Stem Cells
However, failure of such a system...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Feedback Loops

